Registration 333-297734
F-1/A · 2026-09-02 · 0001104659-26-104757
Terms from the governing filing for this registration; not a claim that the offering is open today.
Company research
CIK 2000684Updated Oct 16, 2026
Loading TradingView…
OTC:DVHGF on TradingView ↗We are a biopharmaceutical company focused on developing and commercializing immunomodulatory treatments for inflammatory diseases with high unmet medical needs. Our current portfolio is comprised of treatment candidates with significant potential to address immune-mediated inflammatory diseases. Although inflammation is at the root of several known chronic health conditions1,2,3, we focus on conditions in the areas of dermatology, gastroenterology, hepatology and fibrosis. We have developed a portfolio of patented cosmetic products and are looking for a partner for its commercialization, however, we will primarily be focusing on advancing our therapeutic research and development (“R&D”) pipeline.
No coverage from other publishers is available.
Exhibit 4.2 WARRANT AGENT AGREEMENT WARRANT AGENT AGREEMENT (this “Warrant Agreement”) dated as of _________, 2026 (the “Issuance Date”) between Devonian Health Group Inc., a corporation formed under the laws of Canada (the “Company”), and Continental Stock Transfer & Trust (the “Warrant Agent”). RECITALS WHEREAS, pursuant to the terms of that certain Underwriting Agreement (“Underwriting Agreement”), dated __, 2026, by and among the Company and ThinkEquity LLC, as representative of the unde…
Read attachment ↗Exhibit 99.1 VIA EDGAR July 27, 2026 Division of Corporation Finance Office of Technology Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Devonian Health Group Inc. (CIK 0002000684) Registration Statement on Form F-1 Representation Pursuant to Item 8. A.4 of Form 20-F Ladies and Gentlemen: Devonian Health Group Inc., a foreign private issuer incorporated under the laws of Canada (the "Company"), has included in this Registration on Form F-1 (the "Regi…
Read attachment ↗